# A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

> **NCT00455052** · PHASE1 · COMPLETED · sponsor: **Mersana Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** XMT-1001

## Key facts

- **NCT ID:** NCT00455052
- **Lead sponsor:** Mersana Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455052, "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00455052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*